Department of Otolaryngology Head and Neck Surgery, the Second Hospital, Jilin University, No. 218, Ziqiang Street, Nanguan District, Changchun, 130041, Jilin Province, People's Republic of China.
Department of Oral Geriatrics, School and Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China.
Cell Commun Signal. 2019 Dec 27;17(1):173. doi: 10.1186/s12964-019-0490-8.
Accumulation of immunosuppressive protein programmed death-ligand 1 (PD-L1) has been documented in several cancers and contributes to the evasion of the host immune system. However, cancer cell-intrinsic signaling-dependent control of PD-L1 expression remains to be elucidated. Herein, we aimed to identify the let-7 family of microRNAs as candidates that up-regulate tumor cell PD-L1 expression and mediates immune evasion of head and neck squamous cell carcinoma (HNSCC).
The expression of let-7 family and PD-L1 was quantified in HNSCC tissues and adjacent normal tissues. PD-L1 degradation was evaluated in HNSCC cells in response to elevated expressions of let-7a or let-7b. The regulation of let-7 family on PD-L1 degradation through a mechanism involving T-cell factor-4 (TCF-4) control of β-catenin/STT3 pathway was evaluated. Immune recognition of HNSCC in vivo was examined in subcutaneous tumor-bearing C3H mice in the presence of let-7a/b and/or CTLA-4 antibody.
The let-7 family were significantly down-regulated in the context of HNSCC, sharing a negative correlation with PD-L1 expression. Glycosylated PD-L1 was detected in HNSCC cells, which was reduced by let-7a/b over-expression. TCF-4, the target of let-7a/b, activated the β-catenin/STT3 pathway and promoted PD-L1 degradation. In vivo analysis demonstrated that let-7a/b over-expression potentiated anticancer immunotherapy by CTLA-4 blockade.
Taken together, our findings highlight targeting let-7 family as a potential strategy to enhance immune checkpoint therapy for HNSCC.
在几种癌症中已经记录了免疫抑制蛋白程序性死亡配体 1(PD-L1)的积累,这有助于逃避宿主免疫系统。然而,癌症细胞内在信号依赖性控制 PD-L1 表达仍有待阐明。在此,我们旨在确定 let-7 家族的 microRNAs 作为候选物,这些候选物上调肿瘤细胞 PD-L1 表达并介导头颈部鳞状细胞癌(HNSCC)的免疫逃逸。
定量检测 HNSCC 组织和相邻正常组织中 let-7 家族和 PD-L1 的表达。评估 HNSCC 细胞中 PD-L1 的降解,以响应 let-7a 或 let-7b 的表达升高。通过涉及 T 细胞因子-4(TCF-4)控制β-连环蛋白/STT3 途径的机制,评估 let-7 家族对 PD-L1 降解的调节。在存在 let-7a/b 和/或 CTLA-4 抗体的情况下,在皮下肿瘤荷瘤 C3H 小鼠中体内检查 HNSCC 的免疫识别。
在 HNSCC 背景下,let-7 家族明显下调,与 PD-L1 表达呈负相关。在 HNSCC 细胞中检测到糖基化 PD-L1,let-7a/b 的过表达可降低其水平。let-7a/b 的靶标 TCF-4 激活β-连环蛋白/STT3 途径并促进 PD-L1 降解。体内分析表明,let-7a/b 的过表达增强了 CTLA-4 阻断的抗癌免疫疗法。
总之,我们的研究结果强调了靶向 let-7 家族作为增强 HNSCC 免疫检查点治疗的潜在策略。